<DOC>
	<DOCNO>NCT01670435</DOCNO>
	<brief_summary>This study post-marketing surveillance Japan , local prospective observational study patient receive Ciproxan intravenously first-line treatment sepsis , secondary skin infection follow superficial burn , post-surgical post-traumatic , pneumonia , peritonitis , cholecystitis , cholangitis , anthrax . The objective study ass safety efficacy Ciproxan daily clinical practice . A total 3,000 patient enrol assessed period treatment Ciproxan .</brief_summary>
	<brief_title>Assessment Safety Efficacy Ciproxan-I.V . Daily Clinical Practice - Analysis Results From Post-marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Patients receive Ciproxan firstline treatment eligible study , among sepsis , secondary infection due trauma , burn , surgical wound , pneumonia , peritonitis , cholecystitis , cholangitis , anthrax indication drug . Patients contraindicate base product label .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>sepsis</keyword>
	<keyword>infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>peritonitis</keyword>
	<keyword>cholecystitis</keyword>
	<keyword>cholangitis</keyword>
	<keyword>anthrax</keyword>
</DOC>